Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01568866 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 929
- Enrollment target
NCT01568866: Completed Phase 3 study, sponsored by Amgen.
NCT01568866 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 929 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01568866, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 929 participants
- Enrollment target
Study Summary
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Primary Outcome
Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Participants were evaluated for disease response and progression according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) as assessed by an Independent Review Committee (IRC). Median PFS was estimated using the Kaplan-Meier method. Participants with no baseline disease assessments, starting a new anticancer therapy before do
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 929 participants |
| Start Date | 2012-06-20 |
| Est. Completion | 2018-02-05 |
| Phase | Phase 3 |
What the finished NCT01568866 record still lists
NCT01568866 is an interventional study that assigns participants to a tested intervention. The registered 929 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01568866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01568866 about?
NCT01568866 is a clinical study titled "Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients". The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
What is the current status of trial NCT01568866?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 929 participants. The study started on 2012-06-20. Estimated completion is 2018-02-05.
What interventions are being tested in trial NCT01568866?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01568866?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01568866's enrollment target sits among peer trials
929 339th of 2000 higher than 1,662 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06555029 · 929 participants · NA
Oral Health Intervention in Adult Primary Care
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI